1
|
Adjuvant gemcitabine versus NEOadjuvant gemcitabine/oxaliplatin plus adjuvant gemcitabine in resectable pancreatic cancer: a randomized multicenter phase III study (NEOPAC study).
|
BMC Cancer
|
2011
|
0.97
|
2
|
Impact of surgical margins on overall and recurrence-free survival in parenchymal-sparing laparoscopic liver resections of colorectal metastases.
|
Surg Endosc
|
2014
|
0.82
|
3
|
Safety analysis of the oncological outcome after vein-preserving surgery for colorectal liver metastases detached from the main hepatic veins.
|
Langenbecks Arch Surg
|
2015
|
0.77
|
4
|
Cisplatin-modified de Gramont in second-line therapy for pancreatic adenocarcinoma.
|
Pancreas
|
2013
|
0.75
|
5
|
Exploring limits for data registration in the context of PROCARE, a quality improvement project on rectal cancer.
|
Acta Chir Belg
|
2012
|
0.75
|